Erschienen in:
01.03.2009 | Case Report
Prolonged response to gefitinib in bone metastasis
verfasst von:
Hiroaki Satoh, Hiroichi Ishikawa, Gen Ohara, Norihiro Kikuchi, Kiyohisa Sekizawa
Erschienen in:
Medical Oncology
|
Ausgabe 1/2009
Einloggen, um Zugang zu erhalten
Excerpt
Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, and is regarded as a safe agent, although some toxic effects such as interstitial pneumonia exist [
1,
2]. Gefitinib is now being attempted for patients with advanced non-small cell lung cancer (NSCLC). We herein report a lung adenocarcinoma patient who obtained regression of bone metastasis by gefitinib therapy. …